JP2008521928A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521928A5
JP2008521928A5 JP2007544545A JP2007544545A JP2008521928A5 JP 2008521928 A5 JP2008521928 A5 JP 2008521928A5 JP 2007544545 A JP2007544545 A JP 2007544545A JP 2007544545 A JP2007544545 A JP 2007544545A JP 2008521928 A5 JP2008521928 A5 JP 2008521928A5
Authority
JP
Japan
Prior art keywords
cancer
medicament
group
medicament according
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007544545A
Other languages
English (en)
Japanese (ja)
Other versions
JP5676071B2 (ja
JP2008521928A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/043668 external-priority patent/WO2006060676A1/en
Publication of JP2008521928A publication Critical patent/JP2008521928A/ja
Publication of JP2008521928A5 publication Critical patent/JP2008521928A5/ja
Application granted granted Critical
Publication of JP5676071B2 publication Critical patent/JP5676071B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007544545A 2004-12-03 2005-12-02 腫瘍性疾患を治療するための組成物及び方法 Expired - Lifetime JP5676071B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63316104P 2004-12-03 2004-12-03
US60/633,161 2004-12-03
PCT/US2005/043668 WO2006060676A1 (en) 2004-12-03 2005-12-02 Compositions and methods for treating neoplastic diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012198263A Division JP5837469B2 (ja) 2004-12-03 2012-09-10 腫瘍性疾患を治療するための組成物及び方法
JP2014228602A Division JP5963830B2 (ja) 2004-12-03 2014-11-11 腫瘍性疾患を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2008521928A JP2008521928A (ja) 2008-06-26
JP2008521928A5 true JP2008521928A5 (enExample) 2009-01-22
JP5676071B2 JP5676071B2 (ja) 2015-02-25

Family

ID=36118298

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007544545A Expired - Lifetime JP5676071B2 (ja) 2004-12-03 2005-12-02 腫瘍性疾患を治療するための組成物及び方法
JP2012198263A Expired - Fee Related JP5837469B2 (ja) 2004-12-03 2012-09-10 腫瘍性疾患を治療するための組成物及び方法
JP2014228602A Expired - Fee Related JP5963830B2 (ja) 2004-12-03 2014-11-11 腫瘍性疾患を治療するための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012198263A Expired - Fee Related JP5837469B2 (ja) 2004-12-03 2012-09-10 腫瘍性疾患を治療するための組成物及び方法
JP2014228602A Expired - Fee Related JP5963830B2 (ja) 2004-12-03 2014-11-11 腫瘍性疾患を治療するための組成物及び方法

Country Status (17)

Country Link
US (5) US20070225350A1 (enExample)
EP (1) EP1830838B1 (enExample)
JP (3) JP5676071B2 (enExample)
KR (1) KR101282191B1 (enExample)
CN (2) CN103230394B (enExample)
AU (1) AU2005311709B2 (enExample)
BR (1) BRPI0517135B1 (enExample)
CA (1) CA2588923C (enExample)
DK (1) DK1830838T3 (enExample)
ES (1) ES2396762T3 (enExample)
IL (3) IL183506A (enExample)
MX (1) MX2007006526A (enExample)
NZ (1) NZ555439A (enExample)
PL (1) PL1830838T3 (enExample)
SG (1) SG157365A1 (enExample)
WO (1) WO2006060676A1 (enExample)
ZA (1) ZA200704402B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
ES2402045T3 (es) * 2000-11-16 2013-04-26 The Regents Of The University Of California Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US8217072B2 (en) * 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
JP2007523862A (ja) * 2003-06-20 2007-08-23 ネレアス ファーマシューティカルズ インコーポレイテッド 癌、炎症及び感染性疾患の治療のための、［３．２．０］複素環式化合物およびそれらの類縁体の使用
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7276530B2 (en) * 2004-04-30 2007-10-02 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
JP2008522975A (ja) * 2004-12-03 2008-07-03 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びそれらのアナログを使用する方法
CN103230394B (zh) 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 治疗肿瘤性疾病的化合物及其用途
SG171690A1 (en) * 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
CA2628110A1 (en) * 2005-11-04 2007-05-18 The Regents Of The University Of California Methods of sensitizing cancer to therapy-induced cytotoxicity
WO2008091349A1 (en) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
DK2010168T3 (da) 2006-02-14 2014-07-21 Harvard College Histondeacetylase-inhibitore
NZ596653A (en) 2006-04-06 2012-10-26 Nereus Pharmaceuticals Inc Total synthesis of salinosporamide a and analogs thereof
WO2007130429A2 (en) 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
WO2008124699A1 (en) * 2007-04-06 2008-10-16 Nereus Pharmaceuticals, Inc. A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
BRPI0909661A2 (pt) 2008-03-07 2015-08-11 Nereus Pharmaceuticals Inc Composto e métodos de síntese química e de formação ou preparação de compostos
US7910616B2 (en) 2008-05-12 2011-03-22 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
US20110144155A1 (en) * 2008-06-06 2011-06-16 Schimmer Aaron D 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
EP2321264B1 (en) 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
US20110207627A1 (en) * 2008-08-13 2011-08-25 George Mason University Ex vivo therapeutics screening of living bone marrow cells for multiple myeloma
WO2010099601A1 (en) * 2009-03-05 2010-09-10 University Health Network Use of 5ahq and bortezomib for the treatment of hematological diseases
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US20130173294A1 (en) * 2011-12-30 2013-07-04 Elwha LLC, a limited liability company of the State of Delaware Evidence-based healthcare information management protocols
US10475142B2 (en) 2011-12-30 2019-11-12 Elwha Llc Evidence-based healthcare information management protocols
US10552581B2 (en) 2011-12-30 2020-02-04 Elwha Llc Evidence-based healthcare information management protocols
US10528913B2 (en) 2011-12-30 2020-01-07 Elwha Llc Evidence-based healthcare information management protocols
US10559380B2 (en) 2011-12-30 2020-02-11 Elwha Llc Evidence-based healthcare information management protocols
US10679309B2 (en) 2011-12-30 2020-06-09 Elwha Llc Evidence-based healthcare information management protocols
CN104884637A (zh) * 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
EP3370709A4 (en) * 2015-11-06 2019-12-18 Accuitis Pharmaceuticals, Inc. USE OF PROTEASOME INHIBITORS FOR THE TREATMENT OF EYE DISEASES
US10703760B2 (en) 2016-08-19 2020-07-07 Celgene International Ii Sàrl Morphic forms of marizomib and uses thereof
CN110402144A (zh) * 2017-01-31 2019-11-01 小利兰斯坦福大学托管委员会 抑制ngly1的剂及其使用方法
JP7498475B2 (ja) * 2020-01-31 2024-06-12 株式会社セラバイオファーマ 多発性骨髄腫の治療剤
WO2021183789A1 (en) 2020-03-11 2021-09-16 Trader Darci J Activity-based probes with unnatural amino acids to monitor the proteasome activity
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) * 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
PL177323B1 (pl) * 1993-10-01 1999-10-29 Syntex Inc Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874443A (en) * 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) * 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
US6271199B2 (en) 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
US5922683A (en) * 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
DE69809063T2 (de) * 1997-08-04 2003-06-12 Nihon Nohyaku Co., Ltd. Aryloxyanilin-derivate
NZ503169A (en) 1997-08-15 2001-12-21 Millennium Pharm Inc Synthesis of clasto-lactacystin beta-lactone whereupon the process relies upon a stereoselective addition of a formyl amide to an oxazoline
US6133308A (en) * 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
AU9580098A (en) 1997-09-25 1999-04-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
US20010051654A1 (en) * 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
EP2201945B1 (en) * 1997-11-21 2013-03-06 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
IL137974A0 (en) * 1998-03-26 2001-10-31 Shionogi & Co Indole derivatives having antiviral activity
US6509331B1 (en) * 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
AU762373B2 (en) 1998-10-20 2003-06-26 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20020049157A1 (en) 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
ES2272558T3 (es) 2000-10-12 2007-05-01 Viromics Gmbh Inhibidores del proteasoma para el tratamiento de infecciones causadas por virus de la hepatitis.
ES2402045T3 (es) 2000-11-16 2013-04-26 The Regents Of The University Of California Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación
WO2003084551A1 (de) * 2002-04-05 2003-10-16 Viromics Gmbh Mittel zur behandlung von flaviviridae-infektionen
US7179834B2 (en) * 2002-06-24 2007-02-20 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2004043374A2 (en) 2002-11-06 2004-05-27 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
KR20050098928A (ko) * 2003-02-14 2005-10-12 바이엘 헬스케어 아게 치환된 헤테로사이클
US8217072B2 (en) * 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
JP2007523862A (ja) * 2003-06-20 2007-08-23 ネレアス ファーマシューティカルズ インコーポレイテッド 癌、炎症及び感染性疾患の治療のための、［３．２．０］複素環式化合物およびそれらの類縁体の使用
WO2005094423A2 (en) 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7183417B2 (en) * 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US7276530B2 (en) * 2004-04-30 2007-10-02 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US20060264495A1 (en) * 2004-04-30 2006-11-23 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7579371B2 (en) * 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP1771411A1 (en) 2004-07-12 2007-04-11 Bayer CropScience Aktiengesellschaft Substituted 2-pyrrolidone derivatives as fungicides and insecticides
CN103230394B (zh) * 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 治疗肿瘤性疾病的化合物及其用途
WO2006060609A1 (en) 2004-12-03 2006-06-08 Honeywell International Inc. Gas jet control for inertial measurement unit
WO2006060819A2 (en) 2004-12-03 2006-06-08 The Regents Of The University Of California Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
JP2008522975A (ja) * 2004-12-03 2008-07-03 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びそれらのアナログを使用する方法
WO2006118973A2 (en) 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
US20060287520A1 (en) * 2005-05-16 2006-12-21 Danishefsky Samuel J Synthesis of salinosporamide A and analogues thereof
WO2007021897A1 (en) 2005-08-10 2007-02-22 President And Fellows Of Harvard College Analogs of salinosporamide a
WO2007030662A1 (en) * 2005-09-09 2007-03-15 Nereus Pharmaceuticals, Inc. Biosynthesis of salinosporamide a and its analogs
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
CA2628110A1 (en) * 2005-11-04 2007-05-18 The Regents Of The University Of California Methods of sensitizing cancer to therapy-induced cytotoxicity
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
NZ596653A (en) 2006-04-06 2012-10-26 Nereus Pharmaceuticals Inc Total synthesis of salinosporamide a and analogs thereof
WO2007130404A1 (en) 2006-05-03 2007-11-15 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for the treatment of lung cancer
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
US8088923B2 (en) * 2006-07-07 2012-01-03 The Texas A&M University System Cyclic-fused beta-lactones and their synthesis
WO2008137780A2 (en) 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
BRPI0909661A2 (pt) 2008-03-07 2015-08-11 Nereus Pharmaceuticals Inc Composto e métodos de síntese química e de formação ou preparação de compostos
US7910616B2 (en) 2008-05-12 2011-03-22 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
US8772724B2 (en) 2011-01-05 2014-07-08 Intel-Ge Care Innovations Llc Low power, inexpensive velocity detection using a PIR array

Similar Documents

Publication Publication Date Title
JP2023512175A5 (enExample)
JP2006514689A5 (ja) １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物
JP2023512174A5 (enExample)
JP2013507415A5 (enExample)
TW200626159A (en) Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
JP2005525345A5 (enExample)
JP2009514880A5 (enExample)
JP2018535923A (ja) 胆道癌の治療
JP2017517548A5 (enExample)
JP2009541223A5 (enExample)
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
JP2015536986A5 (enExample)
JP2009514881A5 (enExample)
JP2018517686A5 (enExample)
JP2008535902A5 (enExample)
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
BRPI0513843A (pt) composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato
JP2015532296A5 (enExample)
JP2015520753A5 (enExample)
JP2008528671A5 (enExample)
JP2016525097A5 (enExample)
RU2008138560A (ru) Улучшенные способы лечения опухолей
JP2015535247A5 (enExample)
JP2016502981A5 (enExample)
JP2020523354A5 (enExample)